Package insert for Fulailin saxagliptin tablets covering ingredients, indications, dosage including renal impairment, and adverse reactions.
This is the Chinese package insert (说明书) for Fulailin saxagliptin tablets (沙格列汀片), a medicine whose active ingredient is saxagliptin, with a monohydrate molecular formula of C18H25N3O2·H2O and a molecular weight of 333.43 for the monohydrate and 315.41 for the anhydrous free base. The document carries an approval date of October 27, 2020 and revision dates of May 31, 2021 and June 11, 2024. It is available in two strengths, 2.5 mg (yellow film-coated tablet) and 5 mg (off-white film-coated tablet).
The stated indication is type 2 diabetes, used as monotherapy or in combination with metformin or insulin, and it is not intended for type 1 diabetes or diabetic ketoacidosis. The recommended oral dose is 5 mg once daily regardless of meals, and the tablet must not be cut or split; patients with eGFR below 45 mL/min/1.73 m2 should be limited to 2.5 mg once daily. The insert also reports clinical trial adverse reactions such as upper respiratory tract infection, urinary tract infection, headache, hypoglycemia, peripheral edema and hypersensitivity events. This manual is written in Chinese.
| Active ingredient | Saxagliptin (沙格列汀) |
|---|---|
| Molecular formula | C18H25N3O2·H2O |
| Molecular weight | 333.43 (monohydrate); 315.41 (anhydrous free base) |
| Strengths | 2.5 mg and 5 mg |
| Appearance, 2.5 mg | Yellow film-coated tablet, white after coating is removed |
| Appearance, 5 mg | Off-white film-coated tablet, white after coating is removed |
The stated indication is type 2 diabetes; it can be used as monotherapy or in combination with metformin or insulin.
The recommended oral dose is 5 mg once daily, and the timing does not depend on meals.
No, the tablet must not be cut or split.
Patients with eGFR below 45 mL/min/1.73 m2 should have the dose adjusted to 2.5 mg once daily.